Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of adalimumab discontinuation in stable rheumatoid arthritis remission
2008-004398-16Phase 4Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by Abbott Laboratories. Primary endpoint: Proportion of RA patients maintaining remission after adalimumab discontinuation at 28 weeks. Started Aug 2008; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-004398-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004398-16.